Theranostic SPECT reconstruction for improved resolution: application to radionuclide therapy dosimetry

Theranostic SPECT reconstruction for improved resolution: application to radionuclide therapy dosimetry

Abstract Background SPECT-derived dose estimates in tissues of diameter less than 3× system resolution are subject to significant losses due to the limited spatial resolution of the gamma camera. Incorporating resolution modelling (RM) into the SPECT reconstruction has been proposed as a possible so...

Full description

Bibliographic Details
Main Authors:	H. Marquis, D. Deidda, A. Gillman, K. P. Willowson, Y. Gholami, T. Hioki, E. Eslick, K. Thielemans, D. L. Bailey
Format:	Article
Language:	English
Published:	SpringerOpen 2021-02-01
Series:	EJNMMI Physics
Subjects:	Radionuclide therapy Tumour dosimetry Theranostics Partial volume correction
Online Access:	https://doi.org/10.1186/s40658-021-00362-x

Similar Items

Subcellular Targeting of Theranostic Radionuclides
by: Bas M. Bavelaar, et al.
Published: (2018-09-01)

Diagnostic Performance of Theranostic Radionuclides Used in Transarterial Radioembolization for Liver Cancer
by: Rou Li, et al.
Published: (2021-01-01)

Radionuclide therapy: current status and prospects for internal dosimetry in individualized therapeutic planning
by: Marcelo Tatit Sapienza, et al.

It is time to move forward into the era of Theranostics
by: Hojjat Ahmadzadehfar, et al.
Published: (2018-01-01)

Clinical Perspectives of Theranostics
by: Shozo Okamoto, et al.
Published: (2021-04-01)

Personalized Dosimetry for Radionuclide Therapy Using Molecular Imaging Tools
by: Michael Ljungberg, et al.
Published: (2016-11-01)

Multi-scale dosimetry for targeted radionuclide therapy optimisation
by: Marcatili, Sara
Published: (2015)

The Beginning and Development of the Theranostic Approach in Nuclear Medicine, as Exemplified by the Radionuclide Pair 86Y and 90Y
by: Frank Rösch, et al.
Published: (2017-06-01)

Cancer-Associated Fibroblasts as Players in Cancer Development and Progression and Their Role in Targeted Radionuclide Imaging and Therapy
by: Sofia Koustoulidou, et al.
Published: (2021-03-01)

Impact of dead time on quantitative 177Lu-SPECT (QSPECT) and kidney dosimetry during PRRT
by: Alessandro Desy, et al.
Published: (2020-05-01)

A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy
by: Daphne M. V. Huizing, et al.
Published: (2020-06-01)

Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (<sup>111</sup>In)/Yttrium 90 (<sup>90</sup>Y) Ibritumomab Tiuxetan (Zevalin<sup>®</sup>) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels
by: Richard L. Wahl, et al.
Published: (2021-06-01)

Emerging Radionuclides in a Regulatory Framework for Medicinal Products – How Do They Fit?
by: Clemens Decristoforo, et al.
Published: (2021-05-01)

A survivin-driven, tumor-activatable minicircle system for prostate cancer theranostics
by: TianDuo Wang, et al.
Published: (2021-03-01)

188Re(V) Nitrido Radiopharmaceuticals for Radionuclide Therapy
by: Alessandra Boschi, et al.
Published: (2017-01-01)

RetroSPECT: Gallium-67 as a Long-Lived Imaging Agent for Theranostics
by: Dale Bailey, et al.
Published: (2021-01-01)

Applications of carbon dots on tumour theranostics
by: Hao Wu, et al.
Published: (2021-04-01)

Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review
by: Daphne Merel Valerie Huizing, et al.
Published: (2018-08-01)

Editorial: Advances in the Understanding of Tumor Microenvironment: Molecular and Theranostic Imaging
by: Shouju Wang, et al.
Published: (2021-08-01)

Is there an interest to use deuteron beams to produce non-conventional radionuclides?
by: Ferid eHaddad, et al.
Published: (2015-05-01)

Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management
by: Alexandre Chicheportiche, et al.
Published: (2020-01-01)

Production of Sm-153 With Very High Specific Activity for Targeted Radionuclide Therapy
by: Michiel Van de Voorde, et al.
Published: (2021-07-01)

Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma
by: Julie Bolcaen, et al.
Published: (2021-06-01)

Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights
by: Starr JS, et al.
Published: (2020-04-01)

Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup>Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms
by: Ulrika Jahn, et al.
Published: (2021-02-01)

Continuing Nuclear Data Research for Production of Accelerator-Based Novel Radionuclides for Medical Use: A Mini-Review
by: Syed M. Qaim, et al.
Published: (2021-04-01)

Investigation of post-therapeutic image-based thyroid dosimetry using quantitative SPECT/CT, iodine biokinetics, and the MIRD’s voxel S values in Graves’ disease
by: Naotoshi Fujita, et al.
Published: (2020-01-01)

Biomarkers in Prostate-Specific Membrane Antigen Theranostics
by: Panagiotis J. Vlachostergios, et al.
Published: (2021-06-01)

Nuclear medicine and molecular imaging in clinical practice: yesterday, today and tomorrow
by: Vladimir B. Sergienko, et al.
Published: (2021-04-01)

Biokinetic and dosimetric aspects of 64CuCl2 in human prostate cancer: possible theranostic implications
by: Sergio Righi, et al.
Published: (2018-03-01)

Feasibility and accuracy of single time point imaging for renal dosimetry following 177Lu-DOTATATE (‘Lutate’) therapy
by: Kathy P. Willowson, et al.
Published: (2018-12-01)

Estimation of kidney and bladder radionuclide activity for patients undergoing bone scan
by: Luc T. Bambara, et al.
Published: (2015-07-01)

Radiomics Analysis for <sup>177</sup>Lu-DOTAGA-(l-y)fk(Sub-KuE) Targeted Radioligand Therapy Dosimetry in Metastatic Prostate Cancer—A Model Based on Clinical Example
by: Eve Kelk, et al.
Published: (2021-02-01)

Development of 153Sm-DTPA-SPION as a theranostic dual contrast agents in SPECT/MRI
by: Amir Gholami, et al.
Published: (2016-10-01)

Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey
by: Katarina Sjögreen Gleisner, et al.
Published: (2017-12-01)

Approach to radionuclide therapy dosimetry planning
by: Yu.V. Lysak, et al.
Published: (2016-12-01)

Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT)
by: Alexandre Chicheportiche, et al.
Published: (2018-06-01)

Human dosimetry of free 211At and meta-[211At]astatobenzylguanidine (211At-MABG) estimated using preclinical biodistribution from normal mice
by: Naoyuki Ukon, et al.
Published: (2020-09-01)

Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT
by: Michela Del Prete, et al.
Published: (2018-10-01)

Biodistribution and radiation dosimetry of [64Cu]copper dichloride: first-in-human study in healthy volunteers
by: M.A. Avila-Rodriguez, et al.
Published: (2017-12-01)